Q32 Bio, a clinical-stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, placebo-controlled Phase 2 study (NCT06018428) evaluating the safety and efficacy of bempikibart (formerly ADX-914) in adults with severe alopecia areata. Alopecia areata is an…
San Diego, CA – Biotechnology company Inmagene today announced an important milestone in the development of a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss. The company has dosed the first patient in a Phase 2a clinical trial evaluating IMG-007, an anti-OX40 monoclonal antibody engineered to have an extended half-life….
Legacy Healthcare announced today that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) for Coacillium for the treatment of moderate and severe alopecia areata in children and adolescents. Alopecia areata is an autoimmune disorder that causes hair loss. It affects about 2% of the population, and children and adolescents are…